ProPhase LabsPRPH -5.77% Forward PE Ratio is 0.01 as of Jul. 06, 2026. The stock has 5 warning signs investors should review. Among 87 Medical Diagnostics & Research companies, ProPhase Labs ranks better than 98.85% on this metric.
ProPhase Labs (OTCPK:PRPH) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
ProPhase Labs Forward PE Ratio Related Terms
ProPhase Labs Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for ProPhase Labs's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ProPhase Labs Forward PE Ratio Chart
ProPhase Labs Annual Data
Trend
2021-12
2024-12
Forward PE Ratio
62.50
1.33
ProPhase Labs Quarterly Data
2021-03
2021-06
2021-09
2021-12
2022-03
2022-06
2024-12
2025-03
Forward PE Ratio
3.17
7.46
6.35
62.50
27.78
43.48
1.33
0.87
PRPH vs IDTA, IVRO, FUNI: Forward PE Ratio Comparison
For the Diagnostics & Research subindustry, ProPhase Labs's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ProPhase Labs Forward PE Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, ProPhase Labs's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where ProPhase Labs's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
ProPhase Labs (PRPH) has a Forward PE Ratio of 0.01 as of Jul. 06, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on ProPhase Labs and its competitors. According to the industry distribution chart, ProPhase Labs ranks #1 out of 87 companies in the Medical Diagnostics & Research industry, placing it in the top 1.1%.
Is ProPhase Labs' Forward PE Ratio too high?
ProPhase Labs' current Forward PE Ratio is 0.01. The Medical Diagnostics & Research industry median Forward PE Ratio is 21.57. ProPhase Labs' value of 0.01 is 100% below this industry median. Based on the distribution chart, ProPhase Labs ranks #1 out of 87 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does ProPhase Labs' Forward PE Ratio compare to IDTA and IVRO?
According to the Medical Diagnostics & Research industry distribution chart, ProPhase Labs ranks #1 out of 87 companies for Forward PE Ratio. This places ProPhase Labs in the top 1% of its industry — outperforming the majority of peers. The industry median Forward PE Ratio is 21.57. ProPhase Labs' value of 0.01 is 100% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Medical Diagnostics & Research company?
The median Forward PE Ratio among Medical Diagnostics & Research companies is 21.57, based on 87 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ProPhase Labs's current Forward PE Ratio of 0.01 is 100% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on ProPhase Labs and its competitors. For the Medical Diagnostics & Research industry, the median Forward PE Ratio is 21.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ProPhase Labs's current Forward PE Ratio is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProPhase Labs stock overvalued right now?
Based on GuruFocus' analysis, ProPhase Labs (PRPH) is currently considered Possible Value Trap. The stock's GF Value™ is $0.85, compared to a current price of $0.07 — trading 91.4% below its estimated fair value. The current Forward PE Ratio is 0.01 and 100% below the Medical Diagnostics & Research industry median of 21.57. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For ProPhase Labs (PRPH), the current Forward PE Ratio is 0.01 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ProPhase Labs Inc oriented and diversified next generation biotech, genomics and consumer products company that develops and commercializes novel drugs, dietary supplements, and compounds, and human genomic testing. It offer whole genome sequencing and related services. It maintain two operating segments: diagnostic services (which includes its COVID-19 and other diagnostic testing services) and consumer products. It generates majority of revenue from consumer products segment which engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRPH has been successfully added to your